Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence

[1] Hartnett ME(2012)Mechanisms and management of retinopathy of prematurity N Engl J Med 367 2515-2526

[2] Penn JS(2014)Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial JAMA Ophthalmol 132 1327-1333

[3] Geloneck MM(2011)Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 603-615

[4] Chuang AZ(2018)Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity Ophthalmol Retin 2 942-948

[5] Clark WL(2015)A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity PLoS One 10 e0129383-247

[6] Mintz-Hittner HA(2020)Hypertension and ischemic stroke after aflibercept for retinopathy of prematurity Int Med Case Rep J 13 243-1015

[7] Kennedy KA(2021)Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors Int J Retin Vitr 7 5-1081

[8] Chuang AZ(2015)Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis Ophthalmology 122 1008-259

[9] Roohipoor R(2010)Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment Arch Ophthalmol 128 1080-1855

[10] Karkhaneh R(2017)Reactivation of retinopathy of prematurity three years after treatment with bevacizumab Ophthalmic Surg Lasers Imaging Retina 48 255-1803

[1] Hartnett ME(2012)Mechanisms and management of retinopathy of prematurity N Engl J Med 367 2515-2526

[2] Penn JS(2014)Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial JAMA Ophthalmol 132 1327-1333

[3] Geloneck MM(2011)Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 603-615

[4] Chuang AZ(2018)Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity Ophthalmol Retin 2 942-948

[5] Clark WL(2015)A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity PLoS One 10 e0129383-247

[6] Mintz-Hittner HA(2020)Hypertension and ischemic stroke after aflibercept for retinopathy of prematurity Int Med Case Rep J 13 243-1015

[7] Kennedy KA(2021)Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors Int J Retin Vitr 7 5-1081

[8] Chuang AZ(2015)Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis Ophthalmology 122 1008-259

[9] Roohipoor R(2010)Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment Arch Ophthalmol 128 1080-1855

[10] Karkhaneh R(2017)Reactivation of retinopathy of prematurity three years after treatment with bevacizumab Ophthalmic Surg Lasers Imaging Retina 48 255-1803